Skip to content
MARKETS / BALCAO / GCAN
BALCAO · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Trafalgar International, Inc. GCAN

11 fiscal years on record · USD · FY2025 reported · SEC filings only
$-331,612
In brief

What this company does

Green C was the owner of an exclusive, worldwide license for an eluting transmucosal patch platform (“ETP”) for non-invasive drug delivery in the cannabis field as further described in the exclusive license agreement dated June 21, 2018 with Pharmedica Ltd. Accordingly, on October 19, 2021 the Company entered into a license agreement with Shaare Zedek Scientific Ltd. (“SZS”), the technology transfer arm of Jerusalem’s Shaare Zedek Medical Center (SZMC). The license agreement covers the license of SZS’s novel cannabinoid therapeutic focused on treatment of autism, schizophrenia, Parkinson’s disease, Alzheimer’s disease and other neuropsychiatric disorders. The Company received approval from the Israel Ministry of Health to proceed with a Phase II Clinical Trial as communicated by the Company in a press release on July 5, 2023. We have one person providing us services on a full-time basis, our chief executive officer.

Written from the business description in The Greater Cannabis Company, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 31 March 2026. Every sentence was checked against that document before publication.

Growth
Revenue, FY2025 · full 11-year series below
Revenue $M Net income $M
FY2021 · Revenue 0.0 · Net income -0.6
-0.8M-1.6M201520172019202120232025
Compound annual growth
−49.0%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
Operating margin Net margin
FY2021 · Operating -2716.9% · Net -4768.2%
-100000%-200000%-300000%201520172019202120232025
ROE

Not applicable: equity was negative in this period, so return on equity has no meaning.

Cash & shareholders
returned in FY2025 · dividends + net buybacks

Total assetsUSD 815.00
EquityUSD -741,649.00
Current ratio0.00×

Equity funds -91000% of total assets.

The 11-year record
11 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 20252024202320222021202020192018201720162015
Revenue $B····0.00.00.00.00.0··
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0·
EBITDA $B···········
Income tax $B···········
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $0.000.000.000.000.00−0.01−0.05−0.03−0.030.00·
Dividend / sh $···········
Payout %···········
ROE %···········
Shares out B0.000.000.800.730.510.460.040.030.000.03·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 39 reconciliationsAUDITED

Reconciled in 11 of 19 fiscal years. 56 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onOTC market
Incorporated inFlorida
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2015

Share this section

Download image